Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AZRX NASDAQ:GHSI NASDAQ:NTEC NASDAQ:NVUS OTCMKTS:ULUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZRXAzurRx BioPharma$5.63+7.4%$4.04$3.36▼$26.30$52.51M1.51628,703 shs309,428 shsGHSIGuardion Health Sciences$3.22-2.1%$3.24$3.04▼$18.00$4.35M0.73105,261 shs4,700 shsNTECIntec Pharma$13.52$8.80▼$36.88$8.65M0.83543,436 shs988,300 shsNVUSNovus Therapeutics$2.72-0.7%$13.23$4.50▼$27.32$3.91M2.0778,851 shs673,433 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZRXAzurRx BioPharma0.00%+20.46%+66.35%+987.81%+1,010.17%GHSIGuardion Health Sciences0.00%0.00%0.00%0.00%-0.92%NTECIntec Pharma0.00%0.00%0.00%0.00%0.00%NVUSNovus Therapeutics0.00%-3.52%+13.22%-29.92%+2.24%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZRXAzurRx BioPharma$5.63+7.4%$4.04$3.36▼$26.30$52.51M1.51628,703 shs309,428 shsGHSIGuardion Health Sciences$3.22-2.1%$3.24$3.04▼$18.00$4.35M0.73105,261 shs4,700 shsNTECIntec Pharma$13.52$8.80▼$36.88$8.65M0.83543,436 shs988,300 shsNVUSNovus Therapeutics$2.72-0.7%$13.23$4.50▼$27.32$3.91M2.0778,851 shs673,433 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZRXAzurRx BioPharma0.00%+20.46%+66.35%+987.81%+1,010.17%GHSIGuardion Health Sciences0.00%0.00%0.00%0.00%-0.92%NTECIntec Pharma0.00%0.00%0.00%0.00%0.00%NVUSNovus Therapeutics0.00%-3.52%+13.22%-29.92%+2.24%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAZRXAzurRx BioPharma 0.00N/AN/AN/AGHSIGuardion Health Sciences 0.00N/AN/AN/ANTECIntec Pharma 0.00N/AN/AN/ANVUSNovus Therapeutics 0.00N/AN/AN/AULURULURU 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AGHSIGuardion Health Sciences$12.25M0.35$0.14 per share23.15$6.39 per share0.50NTECIntec PharmaN/AN/AN/AN/A$16.18 per shareN/ANVUSNovus TherapeuticsN/AN/AN/AN/A$13.13 per shareN/AULURULURUN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AGHSIGuardion Health Sciences$160K$4.870.66∞N/A22.79%-73.69%-48.17%N/ANTECIntec Pharma-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/ANVUSNovus Therapeutics-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/AULURULURUN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AGHSIGuardion Health Sciences$5.00155.28%N/A102.67%N/ANTECIntec PharmaN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/AULURULURUN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAZRXAzurRx BioPharmaN/A1.331.33GHSIGuardion Health SciencesN/A16.6816.59NTECIntec PharmaN/A2.342.34NVUSNovus TherapeuticsN/A18.7818.78ULURULURUN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAZRXAzurRx BioPharma6.27%GHSIGuardion Health Sciences20.21%NTECIntec Pharma22.37%NVUSNovus TherapeuticsN/AULURULURUN/AInsider OwnershipCompanyInsider OwnershipAZRXAzurRx BioPharma7.30%GHSIGuardion Health Sciences1.32%NTECIntec Pharma3.30%NVUSNovus Therapeutics2.20%ULURULURU1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableGHSIGuardion Health Sciences101.35 million1.33 millionNot OptionableNTECIntec Pharma40898,000N/AOptionableNVUSNovus Therapeutics71.44 millionN/ANot OptionableULURULURU230.57 million30.24 millionNot OptionableNVUS, GHSI, ULUR, NTEC, and AZRX HeadlinesRecent News About These CompaniesTwo years on from the Voice referendum, its architects remain committed to the cause2 hours ago | sbs.com.auSDestination NT to launch in Top End: Dynamic new tourism initiativeOctober 6, 2025 | ntnews.com.auNReggie Uluru presents first international exhibition in New YorkOctober 1, 2025 | couriermail.com.auCWhere Do We Go From Here? Two Years On From The Indigenous Voice to Parliament Referendum.September 25, 2025 | marieclaire.com.auMAtomic 212° wraps Uluru conference focused on insights, creativity and storytellingSeptember 25, 2025 | campaignbrief.comCUluru Ayers Rock Explained in under 3 minutesSeptember 25, 2025 | msn.comLife on the Road: Van Life Adventures in Uluru, AustraliaSeptember 23, 2025 | msn.comRocking the silver screenSeptember 23, 2025 | australiangeographic.com.auANTIBN CEO Naomi Anstess says US-backed company buying Ayers Rock Resort is ‘anti Australian’September 20, 2025 | ntnews.com.auNBarefoot and freezing: Nova Peris reflects on Sydney Olympics 25 years onSeptember 18, 2025 | sbs.com.auSHelloworld Travel announces NT as destination for 2026 Global Stars and Mega Stars programSeptember 16, 2025 | travelweekly.com.auTMiranda Tapsell asked about controversy surrounding influencer’s taking photos at UluruSeptember 16, 2025 | 7news.com.au7'You are going to someone’s house': Indigenous actress Miranda Tapsell slams Aussie influencers over viral Uluru contentSeptember 15, 2025 | skynews.com.auSMiranda Tapsell blasts influencers overtaking Uluru: ‘You are going to someone’s house’September 13, 2025 | news.com.auNJourney Beyond inch closer to$300m Uluru deal with Voyages Indigenous Tourism AustraliaSeptember 12, 2025 | ntnews.com.auNJetstar drops massive $120 spring sale to popular tourist destinationSeptember 11, 2025 | skynews.com.auSUluru’s only resort set to land new private equity-backed ownerSeptember 11, 2025 | afr.comJetstar launches NT sale to grow Top End and Red Centre tourismSeptember 10, 2025 | travelweekly.com.auTJetstar drops insane $129 sale to hotspotSeptember 10, 2025 | news.com.auNJetstar Unveils Big NT Sale to Boost TourismSeptember 10, 2025 | miragenews.comMMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 20253 Fintech Stocks That Are Set to Rise as Rates FallBy Gabriel Osorio-Mazilli | October 6, 2025NVUS, GHSI, ULUR, NTEC, and AZRX Company DescriptionsAzurRx BioPharma NASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.Guardion Health Sciences NASDAQ:GHSIGuardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.Intec Pharma NASDAQ:NTECIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.Novus Therapeutics NASDAQ:NVUSNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.ULURU OTCMKTS:ULURULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
